A look back at a transformative year for pharma
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
How CSOs can look to the future to forge successful relationships with pharma
Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen
The implications of adalimumab’s European patent expiry
The annual PharmaTimes Marketer of the Year and Communications Team of the Year awards ceremonies took place last night at the Tower Hotel London, with a special addition for this year – the PharmaTimes Sales Awards.
16th November 2018
The Brexit Health Alliance (BHA) has welcomed the agreement on the terms of the UK’s withdrawal from the European Union (EU).
16th November 2018
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
16th November 2018
Shire says it presented data showing that its experimental drug lanadelumab provides a significant and clinically meaningful reduction of hereditary angioedema (HAE) attacks.
16th November 2018
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
16th November 2018
For pharmaceutical and life sciences firms, a case-by-case approach to information and content management has been prevalent for too long
We spoke to Medidata’s General Manager and Senior Vice President EMEA Christian Hebenstreit at the New York NEXT conference to find out how virtual trials could change R&D
Tips for becoming compliant
A review of the UK Bribery Act could mean pharma needs to adapt to changes in legislation
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
This year pharma began to turn its eye towards the power of the microbiome
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
The true impact of biosimilars is starting to be felt across the industry
...But this year its impact, and the potential for change, was felt across the pharma industry
The biggest cases of the past year
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
Ashfield wants to change the perception of CSOs and their role within pharma
The one consistent theme in today’s market place is complexity
Many of us recognise that we need others’ knowledge to address the opportunities and challenges we face, yet we still lack the time or motivation to collaborate
The connectivity made possible by the Internet of Things (IoT) has provided new opportunities for businesses to put their buildings to work and reap the rewards
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
